An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) for Brain Metastasis in HER2+ Breast Cancer
Phase 4
10
about 3.2 years
18+
1 site in CA
What this study is about
This trial is testing an investigational scan called 64Cu-DOTA-trastuzumab PET/MRI to see if it can help find HER2+ breast cancer that has spread to the brain. The scan may also show whether the cancer cells take up trastuzumab, which could predict how well they will respond to a standard chemotherapy drug.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Copper Cu 64-DOTA-Trastuzumab
- 2.Receive Trastuzumab
- 3.Receive Trastuzumab Deruxtecan
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells), trastuzumab deruxtecan
injection, intravenous, infusion
Secondary: Progression-free Survival
imaging